BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

7.815 +0.375 (+5.04%)

Streaming Delayed Price Updated: 12:34 PM EDT, Jun 25, 2026 Add to My Watchlist

Price and Volume

Volume	156,937
Open	7.450
Bid (Size)	7.790 (600)
Ask (Size)	7.840 (1,200)
Prev. Close	7.440
Today's Range	7.390 - 8.020
52wk Range	7.000 - 14.87
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Via The Motley Fool

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.

Via The Motley Fool

Performance

YTD	-36.4%	-36.4%
1 Month	-6.6%	-6.6%
3 Month	-15.5%	-15.5%
6 Month	-35.9%	-35.9%
1 Year	-37.2%	-37.2%

More News

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

Via The Motley Fool

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗

May 15, 2026

Via The Motley Fool

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗

May 15, 2026

Via The Motley Fool

Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗

May 15, 2026

Via The Motley Fool

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 12, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

April 22, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

April 22, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

April 21, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

What's going on in today's after hours session ↗

April 20, 2026

Via Chartmill

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

April 20, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 18, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Via The Motley Fool

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Via The Motley Fool

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Via The Motley Fool

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

March 06, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

March 05, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT to Participate in Upcoming Investor Healthcare Conferences

February 12, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 11, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 13, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

January 07, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Oncology Therapeutics, Inc. - Common Stock publicly traded?

Yes, BridgeBio Oncology Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Oncology Therapeutics, Inc. - Common Stock trade on?

BridgeBio Oncology Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock?

The ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock is BBOT on the Nasdaq Stock Market

What is the current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock?

The current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock is 7.815

When was BridgeBio Oncology Therapeutics, Inc. - Common Stock last traded?

The last trade of BridgeBio Oncology Therapeutics, Inc. - Common Stock was at 06/25/26 12:34 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.